Johnson & Johnson (NYSE: JNJ) on Tuesday, plunged -0.03% from the previous trading day, before settling in for the closing price of $190.9. Within the past 52 weeks, JNJ’s price has moved between $140.68 and $192.10.
Healthcare Sector giant saw their annual sales surged by 0.55% over the last five years. The company achieved an average annual earnings per share of 8.78%. With a float of $2.41 billion, this company’s outstanding shares have now reached $2.41 billion.
The firm has a total of 139800 workers. Let’s measure their productivity.
Johnson & Johnson (JNJ) Breakdown of a Key Holders of the stock
Observing investor behavior towards Drug Manufacturers – General industry stocks is more important than anything else. The insider ownership of Johnson & Johnson is 0.12%, while institutional ownership is 73.91%. The most recent insider transaction that took place on Sep 04 ’25, was worth 10,040,883. In this transaction EVP, WWC. Innovative Medicine of this company sold 56,471 shares at a rate of $177.81, taking the stock ownership to the 178,013 shares. Before that another transaction happened on Sep 04 ’25, when Company’s Officer proposed sale 56,471 for $177.81, making the entire transaction worth $10,040,904.
Johnson & Johnson (JNJ) Recent Fiscal highlights
As on 12/31/2024, Multinational firm has announced its last quarter scores, in which it reported 2.04 earnings per share (EPS) for the period topping the consensus outlook (set at 2.01) by 0.03. Wall Street market experts anticipate that the next fiscal year will bring earnings of 2.75 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 8.78% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 7.04% during the next five years compared to 0.55% growth over the previous five years of trading.
Johnson & Johnson (NYSE: JNJ) Trading Performance Indicators
Johnson & Johnson (JNJ) is currently performing well based on its current performance indicators. A quick ratio of 0.76 was reported for the most recent quarter. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 4.99. Likewise, its price to free cash flow for the trailing twelve months is 24.78.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is 10.36, a number that is poised to hit 2.55 in the next quarter and is forecasted to reach 11.46 in one year’s time.
